Cohance Lifesciences Limited

rs,

To The Manager Department of Corporate Services BSE Limited 25th Floor, P. J. Towers, Dalal Street, Mumbai - 400 001 To The Manager Listing Department National Stock Exchange of Ind

50 million

ormulations not a blockbusters like others, we only go after the low brand, where volume is 40 to 50 million average. If we do 3 to 4 million in the generic space and not many people will fight for that. Wh

4 million

e others, we only go after the low brand, where volume is 40 to 50 million average. If we do 3 to 4 million in the generic space and not many people will fight for that. When we started this, we started wi

25%

exercise we do so the Casper Pharma we took it because we have bonus of pricing we took last year 25% share. We sold that to a big PU fund, HID partners who owns 60%. The Casper Pharma is owned by on

60%

onus of pricing we took last year 25% share. We sold that to a big PU fund, HID partners who owns 60%. The Casper Pharma is owned by one of the partners of Rising Pharma at that time and so the HID c

10%

me but after that it is not like other than RA molecule. Questionnaire: So would you be having 10% to 15% growth guidance for FY2023. Company Speaker: It is a blended growth on the pharma side,

15%

after that it is not like other than RA molecule. Questionnaire: So would you be having 10% to 15% growth guidance for FY2023. Company Speaker: It is a blended growth on the pharma side, Questi

50%

ally for any day while sleeping also then they said okay I will give a good price but they want a 50%, I mean, 60% why not I take my all these peoples and does not handle in giving things which was r

10 million

I said it will be at the end of 2023-2024 it will be launched, these values will be $7 to $8 to $10 million so what we have guided, in our guidance and it comes to the pharma clients since it is depending

20%

these ramp up can happen, but that happened once in 2014, 2015, after that it is normal growth of 20%, 25% which is happening, so that is a challenge we have to guide you on whatever, we do not know

23%

, we do not know our sales, but based on the trends and we have 10% to 15% guarantee, but outside 23% there is a likelihood of downside also sometimes it can happen because the repeat business may no

5%

growth potential on the other side all in all we say it is a flat growth for now may be positive 5%, but right now it says around flat growth. With respect to the formulations and I said this is a

“So, we will be supplying the cost-plus basis and then we will be getting some profit share on the products and all the R&D projects of Rising pharma will come exclusively to Casper Pharma for the next seven years.”

“Their products we sold through the distribution and profit-sharing basis but Rising has their own R&D and no manufacturing, so this is a phase they have a contract for seven years on exclusive basis to set all their R&D projects for tech transfer will be done by Casper and filing will be done by Casper and sold at cost plus basis like any other aspect and we will make profit sharing with the molecules.”

“They have so many customers so they will give them so many products they are identifying some projects on their own and we will be doing in their own facility and for that they have the contract already last year itself before we got this, we do not have Casper Pharma at that time.”

“Here they are doing everything and this is a seven-year contract and if the prices will be paid for this book value only.”

“Unfortunately, things did not move because of the COVID and hope that things will start sometime next year, but it will take three to four years before you see any opportunity to bid on it.”

“Similarly, they also cut down the number of things they are working with so it is a seamless transition from phase to phase and also less project management.”

“It is a huge project management for them.”

“We are doing one R&D project which matured in phase one, two, three and even finally launched and when we did that project we did in a private plant in the R&D centre.”

“Now we are hoping that it will move next year onwards and it will take three to four years before you see.”

“But when it becomes to the generic the concept or let us call it life cycle management that is where people like us will be coming.”

Company Speaker

116

Questionnaire

110

Speaker

3

Question

1

Unknown Speaker

1

Questionnaire

Thank you very much Sir for this and Sir just I mean we probably already got this question many times but like this whole foray and now a bigger commitment to generics and ANDA manufacturing, just trying to understand like because the current setup will be more of a contract manufacturing sort of set up right, for Casper, so?

Company Speaker

No, not the risk of pricing. It is not contract manufacturing. It is profit share. So, we will be supplying the cost-plus basis and then we will be getting some profit share on the products and all the R&D projects of Rising pharma will come exclusively to Casper Pharma for the next seven years.

Company Speaker

They have 15 under development. Two of them are already filed and we are expecting the FDA audit within three months. Then commercialization takes place. Then the additional filings are happening.

Company Speaker

To Casper yes. Rising R&D projects, see Rising has some 15 odd customers. Their products we sold through the distribution and profit-sharing basis but Rising has their own R&D and no manufacturing, so this is a phase they have a contract for seven years on exclusive basis to set all their R&D projects for tech transfer will be done by Casper and filing will be done by Casper and sold at cost plus basis like any other aspect and we will make profit sharing with the molecules.

Company Speaker

Yes, they have R&D. They have so many customers so they will give them so many products they are identifying some projects on their own and we will be doing in their own facility and for that they have the contract already last year itself before we got this, we do not have Casper Pharma at that time.

Questionnaire

Just coming back and you are like businesses doing well? It is very profitable so just trying to understand from a strategic standpoint why this foray into?